Literature DB >> 19079169

Chlamydia trachomatis infection: host immune responses and potential vaccines.

L Hafner1, K Beagley, P Timms.   

Abstract

Chlamydia trachomatis causes genital tract infections that affect men, women, and children on a global scale. This review focuses on innate and adaptive immune responses in the female reproductive tract (FRT) to genital tract infections with C. trachomatis. It covers C. trachomatis infections and highlights our current knowledge of genital tract infections, serovar distribution, infectious load, and clinical manifestations of these infections in women. The unique features of the immune system of the FRT will be discussed and will include a review of our current knowledge of innate and adaptive immunity to chlamydial infections at this mucosal site. The use of animal models to study the pathogenesis of, and immunity to, Chlamydia infection of the female genital tract will also be discussed and a review of recent immunization and challenge experiments in the murine model of chlamydial FRT infection will be presented.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19079169     DOI: 10.1038/mi.2007.19

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  33 in total

Review 1.  Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.

Authors:  Christina M Farris; Richard P Morrison
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

Review 2.  Beyond "safe sex"--can we fight adolescent pelvic inflammatory disease?

Authors:  Bahaa Abu Raya; Ellen Bamberger; Nogah C Kerem; Aharon Kessel; Isaac Srugo
Journal:  Eur J Pediatr       Date:  2012-07-10       Impact factor: 3.183

3.  CD103+ lung dendritic cells (LDCs) induce stronger Th1/Th17 immunity to a bacterial lung infection than CD11bhi LDCs.

Authors:  Sudhanshu Shekhar; Ying Peng; Shuhe Wang; Xi Yang
Journal:  Cell Mol Immunol       Date:  2017-02-13       Impact factor: 11.530

4.  CCR7 Deficiency Allows Accelerated Clearance of Chlamydia from the Female Reproductive Tract.

Authors:  Lin-Xi Li; Jasmine C Labuda; Denise M Imai; Stephen M Griffey; Stephen J McSorley
Journal:  J Immunol       Date:  2017-08-11       Impact factor: 5.422

5.  Aerosolized Non-viral Nucleic Acid Delivery in the Vaginal Tract of Pigs.

Authors:  Katrien Remaut; Evelien De Clercq; Oliwia Andries; Koen Rombouts; Matthias Van Gils; Laetitia Cicchelero; Ian Vandenbussche; Sarah Van Praet; Juan Manuel Benito; José Manuel Garcia Fernandéz; Niek Sanders; Daisy Vanrompay
Journal:  Pharm Res       Date:  2015-10-30       Impact factor: 4.200

Review 6.  Animal models for studying female genital tract infection with Chlamydia trachomatis.

Authors:  Evelien De Clercq; Isabelle Kalmar; Daisy Vanrompay
Journal:  Infect Immun       Date:  2013-07-08       Impact factor: 3.441

7.  Guinea pig genital tract lipidome reveals in vivo and in vitro regulation of phosphatidylcholine 16:0/18:1 and contribution to Chlamydia trachomatis serovar D infectivity.

Authors:  Shradha Wali; Rishein Gupta; Jieh-Juen Yu; Adelphe Mfuh; Xiaoli Gao; M Neal Guentzel; James P Chambers; Sazaly Abu Bakar; Guangming Zhong; Bernard P Arulanandam
Journal:  Metabolomics       Date:  2016-03-08       Impact factor: 4.290

Review 8.  Update on Chlamydia trachomatis Vaccinology.

Authors:  Luis M de la Maza; Guangming Zhong; Robert C Brunham
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

9.  CD43-, but not CD43+, IL-10-producing CD1dhiCD5+ B cells suppress type 1 immune responses during Chlamydia muridarum genital tract infection.

Authors:  J M Moore-Connors; H S Kim; J S Marshall; A W Stadnyk; S A Halperin; J Wang
Journal:  Mucosal Immunol       Date:  2014-06-18       Impact factor: 7.313

Review 10.  Future of human Chlamydia vaccine: potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles.

Authors:  Rajnish Sahu; Richa Verma; Saurabh Dixit; Joseph U Igietseme; Carolyn M Black; Skyla Duncan; Shree R Singh; Vida A Dennis
Journal:  Expert Rev Vaccines       Date:  2018-02-06       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.